<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969643</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-001</org_study_id>
    <nct_id>NCT01969643</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-LIV1A in Breast Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic
      breast cancer. Increasing doses of SGN-LIV1A will be given every 3 weeks alone or in
      combination with trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-LIV1A and metabolites</measure>
    <time_frame>Through 3 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival relative to prior therapy</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy SGN-LIV1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy SGN-LIV1A with Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-LIV1A</intervention_name>
    <description>by intravenous infusion every 3 weeks</description>
    <arm_group_label>Combination Therapy SGN-LIV1A with Trastuzumab</arm_group_label>
    <arm_group_label>Monotherapy SGN-LIV1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>6 mg/kg by intravenous infusion every 3 weeks (subsequent to an initial loading dose of 8 mg/kg administered in the first cycle)</description>
    <arm_group_label>Combination Therapy SGN-LIV1A with Trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of breast cancer with radiographic evidence of
             incurable, unresectable, locally advanced or metastatic disease (LA/MBC)

          -  One of the following: a) Triple-negative disease (ER/PR/HER2-negative) and received
             at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting;
             or b) ER- and/or PR-positive/HER2-negative disease and received at least 2 prior
             cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are no longer a
             candidate for hormonal therapy; or c) Combination Arm: HER2-positive disease and
             received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC
             setting.

          -  Positive for LIV-1 expression by central pathology review on archival or newly
             obtained tumor tissue biopsy

          -  Measurable disease

          -  Eastern Cooperative Oncology Group performance status 0 or 1

          -  Combination Arm: adequate heart function

        Exclusion Criteria:

          -  Pre-existing neuropathy Grade 2 or higher

          -  Malignant CNS disease that has not been definitively treated

          -  P-gp inducers/inhibitors or strong CYP3A inducers/inhibitors within 2 weeks before
             first dose

          -  Combination Arm: hypersensitivity to trastuzumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Kostic, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly LaMaster</last_name>
      <phone>205-934-5367</phone>
      <email>lamaster@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Naessig</last_name>
      <phone>310-423-0721</phone>
      <email>Virginia.naessig@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>6520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelle Sowers</last_name>
      <phone>203-737-3472</phone>
      <email>noelle.sowers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Lajos Pusztai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Bailey</last_name>
      <phone>317-274-0933</phone>
      <email>subailey@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Kathy Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Pereira</last_name>
      <phone>617-632-6651</phone>
      <email>annac_pereira@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ian Krop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarice Zuccaro</last_name>
      <phone>313-576-9375</phone>
      <email>zuccaroc@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Amy Weise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Roos</last_name>
      <phone>507-538-7036</phone>
      <email>roos.michelle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Minetta Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaina Joseph</last_name>
      <phone>646-888-5332</phone>
      <email>josephs2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shanu Modi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>30384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Pedigo</last_name>
      <phone>615-329-7274</phone>
      <email>Heather.Pedigo@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Howard Burris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Mesher</last_name>
      <phone>206-288-2056</phone>
      <email>mollerup@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Specht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Monomethyl auristatin E</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>Metastatic</keyword>
  <keyword>LIV-1 protein, human</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
